ReviewInternational journal of molecular sciences2021
Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Serum 1H NMR-Based Untargeted Metabolomics for Noninvasive Early Detection of Breast Cancer.Journal of proteome research · 2026Article
- Metabolomic properties of the fluid from the surgical ligation after breast-conserving therapy and intraoperative radiotherapy.Scientific reports · 2026Article
- NMR-based metabolomics analysis in breast cancer patients from Saudi Arabia: a pilot study.Scientific reports · 2026Article
- Advances in plasma metabolomics detection technology and its clinical applications in lung cancer and other malignancies.Holistic integrative oncology. · 2026Review
- Pitfalls of onco-metabolomics: impact of sample integrity on metabolomic investigations in more than 4500 human serum samples from ten different cohorts.Frontiers in molecular biosciences · 2026Article
- Recommendations for sample selection, collection and preparation for NMR-based metabolomics studies of blood.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Serum metabolite and metal ions profiles for breast cancer screening.Scientific reports · 2024Article
- Multi-omic analysis identifies metabolic biomarkers for the early detection of breast cancer and therapeutic response prediction.iScience · 2024Article
- Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival.International journal of molecular sciences · 2024Article
- Low-Cost Electronic Nose for the Determination of Urinary Infections.Sensors (Basel, Switzerland) · 2023Article
- Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.iScience · 2023Article
- Review
- Benchtop NMR-Based Metabolomics: First Steps for Biomedical Application.Metabolites · 2023Review
- A Pilot Study on Biochemical Profile of Follicular Fluid in Breast Cancer Patients.Metabolites · 2023Article
- Article
- Exploration of Blood Metabolite Signatures of Colorectal Cancer and Polyposis through Integrated Statistical and Network Analysis.Metabolites · 2023Article
- NMR-Based Metabolomics to Evaluate Individual Response to Treatments.Handbook of experimental pharmacology · 2023Article
- Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients.Translational oncology · 2023Article
- Breast cancer detection by analyzing the volatile organic compound (VOC) signature in human urine.Scientific reports · 2022Article
- Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision oncology is an emerging approach in cancer care. It aims at selecting the optimal therapy for the right patient by considering each patient's unique disease and individual health status. In the last years, it has become evident that breast cancer is an extremely heterogeneous disease, and therefore, patients need to be appropriately stratified to maximize survival and quality of life. Gene-expression tools have already positively assisted clinical decision making by estimating the risk of recurrence and the potential benefit from adjuvant chemotherapy. However, these approaches need refinement to further reduce the proportion of patients potentially exposed to unnecessary chemotherapy. Nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for cancer research and has provided significant results in BC, in particular for prognostic and stratification purposes. In this review, we give an update on the status of NMR-based metabolomic studies for the biochemical characterization and stratification of breast cancer patients using different biospecimens (breast tissue, blood serum/plasma, and urine).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.